Product nameAnti-Aconitase 1/ACO1 (phospho S138) antibody
See all Aconitase 1/ACO1 primary antibodies
DescriptionRabbit polyclonal to Aconitase 1/ACO1 (phospho S138)
ab63260 detects endogenous levels of Aconitase 1/ACO1 only when phosphorylated at serine 138.
Tested applicationsSuitable for: ELISA, IHC-Pmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat
Synthetic peptide corresponding to Human Aconitase 1/ACO1.
- Human ovary tissue
This product was previously labelled as Aconitase 1
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol, 0.87% Sodium chloride
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab63260 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
- Pathways and Processes
- Metabolic signaling pathways
- Energy transfer pathways
- Energy Metabolism
Our Abpromise guarantee covers the use of ab63260 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/50 - 1/100.|
FunctionIron sensor. Binds a 4Fe-4S cluster and functions as aconitase when cellular iron levels are high. Functions as mRNA binding protein that regulates uptake, sequestration and utilization of iron when cellular iron levels are low. Binds to iron-responsive elements (IRES) in target mRNA species when iron levels are low. Binding of a 4Fe-4S cluster precludes RNA binding.
Catalyzes the isomerization of citrate to isocitrate via cis-aconitate.
Sequence similaritiesBelongs to the aconitase/IPM isomerase family.
- Information by UniProt
- ACO 1 antibody
- ACO1 antibody
- ACOC_HUMAN antibody
ab63260 has not yet been referenced specifically in any publications.